COMMUNIQUÉS West-GlobeNewswire
-
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity
05/03/2026 -
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
05/03/2026 -
Buck Institute Launches Healthspan Horizons to Make Long-Term Health Measurable and Actionable
05/03/2026 -
Evaxion plans to file 2025 annual report later today
05/03/2026 -
Evaxion announces business update and full year 2025 financial results
05/03/2026 -
Vera Therapeutics Appoints Christopher Hite to Board of Directors
05/03/2026 -
NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2026
05/03/2026 -
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
05/03/2026 -
INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic
05/03/2026 -
Autonomix Medical Selected for Best Innovation Competition at CRT 2026
05/03/2026 -
Children’s Wisconsin and Xealth to Present Key Insights on Scalable Digital Patient Experience Programs at HIMSS26
05/03/2026 -
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
05/03/2026 -
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
05/03/2026 -
CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent
05/03/2026 -
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
05/03/2026 -
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
05/03/2026 -
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
05/03/2026 -
Kestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trial
05/03/2026 -
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting
05/03/2026
Pages